Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent

Author： Khalili P.   Naimi E.   Sun W.Y.   Knaus E.E.   Wiebe L.I.  

Publisher： Elsevier

ISSN： 0928-0987

Source： European Journal of Pharmaceutical Sciences, Vol.19, Iss.4, 2003-07, pp. : 305-313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

By van den Bongard H.J.G. Desirée   Sparidans Rolf W.   Critchley David J.P.   Beijnen Jos H.   Schellens Jan H.M.  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 151-158

Springer Publishing Company

Access to resources Recommend Favorite

Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential

By Scatena Roberto   Bottoni Patrizia   Martorana Giuseppe E   Giardina Bruno  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 835-846

Informa Healthcare

Access to resources Recommend Favorite

Biochemical Aspects of Nitric Oxide

By  

Current Pharmaceutical Design, Vol. 10, Iss. 14, 2004-05 ,pp. : 1627-1645

Bentham Science Publishers

Access to resources Recommend Favorite

Antianginal effects of FR144420, a novel slow nitric oxide-releasing agent

By Hirasawa Y.   Sugimoto T.   Fukuyama S.   Kato Y.   Takamatu H.   Ohno M.   Nishino S.   Kato M.   Maeda K.   Seki J.   Kita Y.  

European Journal of Pharmacology, Vol. 303, Iss. 1, 1996-05 ,pp. : 55-59

Elsevier

Access to resources Recommend Favorite

FR144420, a novel, slow, nitric oxide-releasing agent

By Kita Y.   Ohkubo K.   Hirasawa Y.   Katayama Y.   Ohno M.   Nishino S.   Kato M.   Yoshida K.  

European Journal of Pharmacology, Vol. 275, Iss. 2, 1995-03 ,pp. : 125-130

Elsevier

Access to resources Recommend Favorite